CAR-T Hikes Overall Survival in Relapsed/Refractory LBCL ...Middle East

Medscape - News
CAR T-cell therapy drug axicabtagene ciloleucel significantly improved overall survival compared with standard second-line treatments in patients with early relapsed or refractory large B-cell lymphoma. MDedge News

Hence then, the article about car t hikes overall survival in relapsed refractory lbcl was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CAR-T Hikes Overall Survival in Relapsed/Refractory LBCL )

Apple Storegoogle play

Last updated :

Also on site :